deltatrials
Completed PHASE1 NCT00002196

A Study of CI-1012 in HIV-Infected Patients

A Phase I Multiple Oral, Rising-Dose, Tolerance and Pharmacokinetic Trial of CI-1012 in HIV-1-Infected Volunteers.

Sponsor: Parke-Davis

Conditions HIV Infections
Interventions CI-1012
Updated 5 times since 2017 Last updated: Jun 23, 2005

This PHASE1 trial investigates HIV Infections and is currently completed. Parke-Davis leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Parke-Davis
Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States
  • • Maitland, United States
  • • Palm Springs, United States
  • • San Francisco, United States